Preeclampsia, which affects approximately 5% of pregnancies, is a leading cause of maternal and perinatal death 1 . The causes of preeclampsia remain unclear, but there is evidence for inherited susceptibility 2 . Genome-wide association studies (GWAS) have not identified maternal sequence variants of genome-wide significance that replicate in independent data sets 3, 4 . We report the first GWAS of offspring from preeclamptic pregnancies and discovery of the first genomewide significant susceptibility locus (rs4769613; P = 5.4 × 10 −11 ) in 4,380 cases and 310,238 controls. This locus is near the FLT1 gene encoding Fms-like tyrosine kinase 1, providing biological support, as a placental isoform of this protein (sFlt-1) is implicated in the pathology of preeclampsia 5 . The association was strongest in offspring from pregnancies in which preeclampsia developed during late gestation and offspring birth weights exceeded the tenth centile. An additional nearby variant, rs12050029, associated with preeclampsia independently of rs4769613. The newly discovered locus may enhance understanding of the pathophysiology of preeclampsia and its subtypes.
Our initial GWAS meta-analysis tested 7,476,169 sequence variants in 2,658 offspring from preeclamptic pregnancies (cases) and 308,292 population controls of European descent from Iceland (deCODE cohort) and the UK (GOPEC and ALSPAC cohorts). We observed a single genome-wide significant association with preeclampsia (rs4769613; P = 3.2 × 10 −8 ) located on chromosome 13 near the FLT1 gene (Fig. 1a) . We genotyped rs4769613 and a correlated surrogate in 1,722 independent cases and 1,946 controls from Norway and Finland, along with 26 variants marking GWAS meta-analysis signals elsewhere in the genome with P values that showed suggestive evidence of association (Supplementary Table 1 ). rs4769613 was significantly associated with preeclampsia in the replication data sets (P = 3.6 × 10 −4 ), and joint analysis of the GWAS and replication data yielded robust genome-wide association (P = 5.4 × 10 −11 ) with an allelic odds ratio (OR) of 1.21 for the C allele ( Table 1) . Forest plots showed that the frequency of the C allele was consistently elevated in cases from all GWAS and replication data sets, with no evidence of heterogeneity (P het = 0.678; Supplementary Fig. 1 ). None of the other genotyped loci achieved genome-wide significance (P < 5 × 10 −8 ) in joint analysis of the GWAS and replication data.
We then examined the genomic features of the FLT1 locus in detail (Fig. 1b) and found that some of the association signal remained after conditioning on rs4769613 (Fig. 1b, bottom) . This suggests that other variants near FLT1 might associate with preeclampsia independently of rs4769613. We therefore genotyped the replication data sets for 21 additional variants at the FLT1 locus, representing nine linkage disequilibrium (LD) blocks (Supplementary Table 2 and Supplementary Fig. 2 ). rs12050029 and its surrogates in the same LD block were significant in combined analysis of the GWAS and replication data after region-wide correction in the FLT1 locus for testing of all common variants within 1 Mb of rs4769613 (P = 3.9 × 10 −6 ; Table 1 ). rs149427560 also achieved region-wide significance in the FLT1 locus, but its association signal was weaker than that for rs12050029 ( Table 1) . In summary, our results imply that, in addition to rs4769613, other independent variants near FLT1 may modulate preeclampsia susceptibility.
As expected if the rs4769613[C] risk allele increases susceptibility by acting in the fetal genome, the frequency of the C risk allele in preeclamptic mothers was midway between that in controls and the significantly elevated frequency in the offspring from preeclamptic pregnancies (Supplementary Table 3 ). Offspring from preeclamptic pregnancies also preferentially inherited rs4769613[C] from heterozygous parents in the only data set that had DNA available from both parents, again implying that rs4769613[C] increases susceptibility by acting in the fetal genome (Supplementary Table 4 ). To examine whether rs4769613 exerts effects in both the fetal and maternal genomes, we applied EMIM (estimation of maternal, imprinting and interaction effects using multinomial modeling), an algorithm that simultaneously evaluates preeclamptic mothers, offspring from preeclamptic pregnancies and controls to calculate ORs for preeclampsia risk corresponding to one or two risk alleles carried in the fetus (R 1 , R 2 ) or in the mother (S 1 , S 2 ) 6 . Fetal ORs were significantly above 1.0, and each fetal copy of rs4769613[C] increased the OR (Fig. 2a) . By contrast, maternal ORs were not significantly different from 1.0. We conclude that rs4769613 exerts influence primarily in the fetal genome.
As there is evidence that genetic imprinting may operate in placental development 7 , we examined rs4769613 allele transmission from heterozygous parents but found no difference in transmission associated with parental sex in preeclampsia and, hence, no evidence for imprinting (χ 2 = 0.046, P = 0.83; Supplementary Table 5) . We also applied EMIM 6 to cohorts with DNA available from one or both parents but again found no evidence that maternal and paternal alleles at rs4769613 confer differential risk of preeclampsia (P = 0.90).
Subclassifications of preeclampsia are based on clinical features, in particular, the gestation stage at diagnosis and evidence of fetal 1 2 5 6 VOLUME 49 | NUMBER 8 | AUGUST 2017 Nature GeNetics l e t t e r s growth restriction (FGR) 8 . Early-onset (EO) preeclampsia, which is present in 12-15% of all preeclamptic pregnancies and is defined as preeclampsia with onset before 34 weeks of gestation, is associated with higher maternal and perinatal mortality than later-onset (LO) preeclampsia. It has been proposed that LO preeclampsia results predominantly from maternal maladaptation to the physiological stresses of pregnancy, whereas EO preeclampsia is primarily the result of suboptimal placental implantation into the uterine wall, leading to inadequate placental perfusion and the release of damaging placental factors into the maternal circulation 8 . In keeping with this ; the landscape of chromatin interactions for 31 tissue types inferred using the integrated method for predicting enhancer targets (IM-PET) (see URLs); and conditional −log 10 (P value) for GWAS meta-analysis using logistic regression with rs4769613 as a covariate.
l e t t e r s hypothesis, EO preeclampsia is frequently associated with FGR, resulting in babies who are small for gestational age (SGA) at birth. SGA, defined by a birth weight below the tenth centile, is widely used as a surrogate for FGR.
We assessed the impact of rs4769613 genotype on preeclampsia subtypes, defined by whether preeclampsia was EO or LO and by the presence or absence of SGA birth weight. We noted that rs4769613 [C] occurred at a higher frequency in offspring from LO preeclamptic pregnancies than in those from EO preeclamptic pregnancies (casecontrol OR of 1.23 versus 1.06) and found that the difference was significant in case-case meta-analysis of the two groups (P = 0.017; Fig. 2b) . Similarly, the C allele occurred at a higher frequency in non-SGA preeclampsia cases than in SGA preeclampsia cases (casecontrol OR of 1.25 versus 1.10), and the difference was significant in a case-case comparison (P = 0.019; Fig. 2b ). Further division of the cases in Figure 2b into the four possible subcategories showed that rs4769613[C] conferred the greatest risk to LO + non-SGA cases (case-control OR = 1.26, P = 1.2 × 10 −7 ) and the least risk to EO + SGA cases (case-control OR = 1.03, P = 0.72), with the case-case comparison of these two subcategories showing a significant difference in the risk conferred (P = 5.8 × 10 −3 ). In summary, the results indicate that rs4769613 exerts its greatest influence in pregnancies in which preeclampsia develops in late gestation and the offspring's birth weight exceeds the tenth centile. rs12050029 was also associated with LO preeclampsia, but the strength of the association did not differ between SGA and non-SGA preeclampsia cases (Supplementary Fig. 3 ).
FLT1 encodes a transmembrane tyrosine kinase receptor, Flt-1, that mediates angiogenesis by binding vascular endothelial growth factor A (VEGFA) and placental growth factor (PlGF) 9 . The alternatively spliced soluble isoform, sFlt-1, antagonizes angiogenesis by also binding VEGFA and PlGF. During pregnancy, FLT1 is mainly expressed in fetal trophoblasts predominantly as the sFlt-1 isoform, which is released into the maternal circulation. The excessive release of sFlt-1 in preeclampsia appears to mediate widespread maternal endothelial dysfunction, manifesting as hypertension, proteinuria and vascular compromise of major organs. High sFlt-1 and low PlGF concentrations in maternal blood are established markers of EO preeclampsia 8 , but our evidence that FLT1 polymorphisms are strongly associated with LO preeclampsia suggests that trophoblast function is also important in this preeclampsia subgroup.
The signals around rs4769613 and rs12050029 are both located in placental enhancer regions (Fig. 1b) , suggesting a mechanism through which variants could affect FLT1 expression. We explored a possible association between fetal FLT1 genotype and protein expression by placental immunohistochemistry and intensity scanning in 37 preeclamptic and 44 control pregnancies. There was no detectable association between fetal rs4769613 genotype and trophoblast Flt-1 and sFlt-1 expression in preeclamptic pregnancies (P = 0.47) or controls (P = 0.26). We also examined whether the concentration of sFlt-1 in maternal serum obtained during the first or third trimester of pregnancy was associated with fetal rs4769613 genotype in mother-baby pairs from 242 control and 276 preeclamptic pregnancies. In control pregnancies, there was a trend toward increased maternal serum levels of sFlt-1 with each fetal copy of rs4769613[C] in the third trimester, which reached nominal significance (P = 0.04), whereas in preeclamptic pregnancies sFlt-1 levels were higher than in controls (P < 0.001) but with no detectable difference between the rs4769613 genotype groups (P = 0.47) (Fig. 2c) . We did not have placental tissue suitable for mRNA studies and instead used data from the Genotype-Tissue Expression (GTEx) database. We found no evidence of correlation between genotype at rs4769613 or rs12050029 and FLT1 expression in 42 tissues, although data for placental tissue are not available in this database. Therefore, the evidence that fetal rs4769613 genotype affects maternal serum levels of sFlt-1 is modest. Subtle changes in sFlt-1 concentration driven by fetal FLT1 genotype, which are suggested to occur by the data from control pregnancies, may be masked in preeclampsia, in which the overall levels of sFlt-1 are already high. Also, the effect in control pregnancies is minimal in comparison to the increase in serum sFlt-1 levels seen in preeclamptic pregnancies, so it may not reflect the role of the preeclampsia-associated variants in the pathophysiology of preeclampsia.
We explored whether the preeclampsia-associated variants affect other diseases or traits using the deCODE database of common diseases and traits routinely measured at hospitals and clinical laboratories (Online Methods). Given that rs4769613 and rs12050029 are not in LD ( Supplementary Fig. 2 ), it is noteworthy that the only significant association with a disease or trait in the database for both variants was with red blood cell (RBC) count (P = 5.0 × 10 −4 and P = 1.5 × 10 −7 for rs4769613 and rs12050029, respectively); the preeclampsia risk allele for each variant was consistently associated with reduced RBC count (Supplementary Table 6 ). The RBC association with FLT1 is intriguing as the VEGF ligand of Flt-1 has previously been implicated in regulation of erythropoiesis, but the mode and sites of action are complex 10, 11 . Our preeclampsia results suggest that, in the fetus, the two variants lead to an increase in sFlt-1 levels, whereas the same alleles are associated with reduced RBC count in the general (nonpregnant) population. The effect of these alleles both in preeclampsia and on RBC count is consistent with the variants acting through the neighboring FLT1 gene. Results are ordered by strength of association with preeclampsia in GWAS + replication meta-analysis at three variants near FLT1 that are not in LD. The row for rs4769613 is in bold because the GWAS + replication P value for this SNP is genome-wide significant (P < 5 × 10 −8 ). rs12050029 and rs149427560 are included in the table because their GWAS + replication P values are below the region-wide significance threshold for the FLT1 locus (P = 6.01 × 10 −5 ), as calculated by the method of Gao (see text and Online Methods). n, total cases/controls in meta-analysis; chr. 13 position, NCBI Build 37 position on chromosome 13; risk/alt allele, the allele with the higher frequency in cases versus controls and the alternate allele; RAF, risk allele frequency in UK GWAS controls; covariate, covariate in conditional logistic regression; OR, allelic odds ratio; 95% CI, 95% confidence interval; P, P value from case-control association analysis. Genotype at rs149427560 for the FINNPEC cohort was proxied from rs11619261 (pairwise r 2 = 0.88 in Finland 1000 Genomes Project Phase 3 data).
l e t t e r s
We note that SNP rs4769613 is located between FLT1 and POMP, which encodes proteasome maturation protein, a ubiquitously expressed protein involved in proteasome assembly and major histocompatibility complex (MHC) class I antigen presentation 12 . We cannot exclude the possibility that sequence variants at this locus affect expression of POMP or more distant genes, but the GTEx database does not provide any evidence to support this contention.
Evidence presented here implies that altered FLT1 expression by trophoblasts is not merely a secondary consequence of placental pathology in preeclampsia but is central to its etiology. A role for fetal sequence variants in susceptibility to preeclampsia is consistent with patterns of inheritance implicating both maternal and paternal factors 2 . The fetal FLT1 gene has previously been indirectly implicated in pregnancies with fetal trisomy 13, which are associated with increased placental expression of sFlt-1 and an increased incidence of preeclampsia 13 . sFlt-1 is a marker of placental malfunction, which is a hallmark of EO preeclampsia 8 ; our observation that FLT1 genotype is associated even more strongly with LO preeclampsia implies . Individual data sets (GOPEC, MoBa and FINNPEC) and meta-analysis across the data sets (Meta) show that OR is increased by each fetal copy of the C risk allele: R 1 , P = 3.7 × 10 −4 ; R 2 , P = 3.7 × 10 −9 . By contrast, the ORs for maternal copies (S 1 , S 2 ) are not significantly different from 1, implying that, after accounting for fetal copies, maternal copies of the C allele confer no additional increased risk of preeclampsia. n = 8,557 preeclampsia cases and 8,802 controls, some of whom are related (supplementary table 9). (b) Forest plots showing the preeclampsia (PE) subtypes, defined by early and late onset (EO and LO) and by birth weight that is small for gestational age (SGA) or not (non-SGA). Case-case comparisons, in blue font, show that the C risk allele is more significantly associated with LO preeclampsia and non-SGA preeclampsia than with EO preeclampsia and SGA preeclampsia. Dividing cases into the four possible subcategories showed that the C allele confers the greatest risk of preeclampsia to LO + non-SGA cases and the least risk of preeclampsia to EO + SGA cases. (c) Box-and-whisker plots of sFlt-1 concentration in maternal serum during the first and third trimesters in preeclamptic pregnancies (cases) and controls, showing the effect of the fetal rs4769613 genotype. Boxes span the first to third quartile of sFlt-1 concentration, with horizontal bars within the boxes denoting the median; whiskers extend to the 10th and 90th centiles. The level of sFlt-1 in maternal serum is higher in cases (n = 156) than in controls (n = 47) in the third trimester across all fetal genotypes (t-test ln(sFlt-1): t = 7.79; 200 degrees of freedom (d.f.); two-tailed P < 0.001). In the third trimester controls, each copy of the rs4769613[C] allele carried by the fetus was associated with an increase in sFlt-1 levels (linear regression of ln(sFlt) with SNP genotype (coded as 0, 1 or 2) and gestational age as covariates; P = 0.04).
l e t t e r s that placental pathology is also a feature of late-onset disease. The variants we describe can serve as tools for experimental testing of whether, how, when and where they affect FLT1 expression, and how altered expression relates to the pathophysiology of preeclampsia and its subtypes. The discovery of sequence variants in the fetal genome that increase the risk of disease in the mother is a demonstration of the closeness between the mother and baby in the remarkable symbiosis we call pregnancy. This research also makes use of GWAS data from the ALSPAC study generated by G. Hemani and G. McMahon. The ALSPAC study website contains details on all the data that are available through a fully searchable data dictionary (http://www.bris.ac.uk/alspac/ researchers/data-access/data-dictionary/). We are grateful to all the families from Iceland, Norway, Finland and the UK who took part in this study and for the work of teams of volunteers, managers, midwives, nurses, doctors, computer and laboratory technicians, clerical workers, research scientists and receptionists who made this study possible. 
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oNLINe MeThodS
Cohorts. Three European cohorts of offspring from pregnancies affected by preeclampsia provided cases for GWAS meta-analysis: the GOPEC and ALSPAC cohorts from the UK and the Icelandic deCODE cohort. Two independent cohorts were used for replication genotyping: the Finnish FINNPEC collection and the Norwegian Mother and Child Cohort Study (MoBa). Recruitment criteria were not identical in all cohorts, so subsets were selected for this study on the basis of an internationally recognized definition of preeclampsia 14 : (i) new-onset hypertension after the 20th week of gestation with systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg on at least two occasions and (ii) new-onset proteinuria with ≥0.3 g of protein excreted per 24 h or ≥1 in dipstick analysis of urine. All offspring were from singleton pregnancies in Western European women; offspring from preeclamptic pregnancies in women with a previous history of essential hypertension, type 1 or type 2 diabetes mellitus, ischemic heart disease, cerebrovascular accident or chronic renal disease were excluded. Phenotypic details are summarized in Supplementary Tables 7 and 8. Written informed consent was obtained from participants or from parents on behalf of minors, and all studies were approved by local research ethics committees.
GOPEC (Genetics of Pre-eclampsia).
The UK GOPEC collection includes 1,157 DNA samples from mother-baby pairs with preeclampsia recruited at diagnosis between 1992 and 2009 for genetic studies of preeclampsia 15 . Control data were derived from Wellcome Trust Case Control Consortium 2 (WTCCC2) genome-wide analysis of 2,930 samples from the 1958 Birth Cohort and 2,737 samples from the National Blood Services, providing control data for 5,297 individuals after quality control 16 .
ALSPAC (Avon Longitudinal Study of Parents and Children).
The ALSPAC prospective birth cohort study recruited pregnant women living in southwest England between 1991 and 1992 and has been described elsewhere 17 . The study included 13,678 singleton pregnancies resulting in a live birth. After exclusion of women with existing hypertension, diabetes and gestational diabetes, there were 7,382 pregnancies for which blood pressure, proteinuria measurements and fetal GWAS data were available. Of these, 146 met the definition of preeclampsia and were included. The control group of 6,130 subjects was derived from all other included pregnancies with fetal GWAS data in women not affected by essential hypertension or gestational hypertension.
deCODE preeclampsia cohort. The deCODE preeclampsia cohort is part of an ongoing sample collection including a large part of the Icelandic population. Preeclamptic pregnancies occurring between 1970 and 2009 were identified through scrutiny of hospital records at the Landspitali University Hospital, which provides secondary and tertiary services for the whole of Iceland. Initially, a group of women with hypertensive disease in pregnancy (ICD-9: 642.0-9 and ICD-10: O10-16) in the years 1984-1999 was selected for further study on the basis of familial relationships. All maternity records for these women were scrutinized, and each affected pregnancy was reclassified 18 . This identified 491 singleton preeclamptic pregnancies. Preeclamptic pregnancies from 2000-2009 were identified on the basis of ICD-10 codes (O14-15), yielding 1,311 additional singleton preeclamptic pregnancies. Overall, information on 1,802 singleton preeclamptic pregnancies for 1,662 mothers is available. GWAS data were available for 1,507 offspring of these pregnancies, identified retrospectively on the basis of the national register. The control group comprises 296,865 individuals from the deCODE sample collection.
MoBa (Norwegian Mother and Child Cohort Study).
The Norwegian Mother and Child Cohort Study is a longitudinal study of over 110,000 pregnant women, their children and their partners who were recruited between 1999 and 2008 from maternity units throughout Norway 19 . 1,200 pregnancies affected by preeclampsia were identified from Medical Birth Register of Norway records; the validity of each diagnosis was assessed by retrieval and examination of antenatal records. 1,200 non-hypertensive pregnancies served as the control group. Pregnancies were excluded from case and control groups if a maternal history of essential hypertension, chronic renal disease or diabetes mellitus was recorded in the Medical Birth Registry of Norway.
FINNPEC (Finnish Genetics of Preeclampsia Consortium).
The FINNPEC collection was assembled in Finland between 2008 and 2011 from two recruitment arms 20 . Samples were collected at the time of diagnosis of preeclampsia from 879 mothers and from 922 non-preeclamptic mothers during pregnancy from antenatal and labor wards. Children and partners were also enrolled.
A further 525 pregnancies affected by preeclampsia were identified by examination of hospital records, and women and offspring were invited to participate by letter. After exclusion of pregnancies that did not meet the entry criteria for this study, the offspring of 605 preeclamptic pregnancies were included as cases and the offspring of 800 non-hypertensive pregnancies provided the control group.
Genotyping, quality control, genotype imputation and association analysis in GWAS data sets. GOPEC. The Illumina OmniExpress chip was used to genotype 1,157 offspring from preeclamptic pregnancies; maternal samples, where available, were similarly genotyped. A total of 730,525 variants were called with the GenCall algorithm. We carried out quality control analysis using PLINK (http://zzz.bwh.harvard.edu/plink/) and SMARTPCA 21 . A subset of the samples (186) underwent whole-genome amplification (WGA). Genotype calls from WGA samples can be prone to calling artifacts. To address this, we removed variants with either a low call rate (<95%) or Mendelian errors in the WGA samples, and we then performed a pseudocase-control analysis of WGA versus non-WGA samples and removed variants with significant genotypic association (P < 0.001). We then applied standard quality control to the combined WGA and non-WGA data set on this reduced set of variants (670,435). Briefly, standard quality control comprises the following subject-level exclusion criteria: individual call rate <95%, heterozygosity >3 s.d. from the mean; any of the first three HapMap (based on CEU, YRI, CHB, JPT and GIH populations) principal axes of variation >4 s.d. from the mean; and sex mismatch. Related individuals (identity by descent (IBD) > 0.1) with the lowest call rates were preferentially removed. The variant-level exclusion criteria were as follows: call rate <95%; exact Hardy-Weinberg equilibrium P < 1 × 10 −6 ; minor allele frequency (MAF) <1%; and nonrandom missingness of uncalled genotypes (plink-test-mishap) with Bonferroni-corrected P < 0.05. These filters left 1,005 samples (89 WGA) and 574,919 variants.
We used WTCCC2 population controls from the National Blood Donors Cohort and the UK 1958 Birth Cohort 16 . These samples were genotyped on the Illumina 1.2M chip and variants were called using GenCall. Strand-ambiguous markers were removed, and the standard quality control procedure described above was then applied to the two control data sets. The merged control data set consisted of 5,297 samples and 438,912 variants. This control data set was merged with the case data set, resulting in 429,754 variants after quality control that were genotyped in both cases and controls.
Cases and controls were imputed together with IMPUTE2 (impute_v2.3.0) 22 and SHAPEIT 23 using the prephasing workflow with the 1000 Genomes Project Phase 1 reference panel (December 2013) downloaded from the IMPUTE2 website. Imputation resulted in 10,404,388 biallelic variants with MAF >0.25% that were either directly genotyped or imputed with IMPUTE2 INFO score >0.6.
Post-imputation association analysis was carried out using SNPTEST (v2.4.1) 22 with the "expected" method, including no ancestry principal components as covariates. We calculated the genomic control for variants with MAF >0.5% as λ GC = 1.005.
deCODE. Details of GWAS genotyping, quality control and imputation of the Icelandic data set, including the preeclampsia cases and controls used in this study, have been described 24 . Briefly, samples were assayed with the Illumina HumanHap300, HumanCNV370, HumanHap610, HumanHap1M, HumanHap660, Omni-1, Omni2.5 or OmniExpress chip at deCODE Genetics. Following quality control, a final set of 676,913 autosomal SNPs was used for long-range phasing of all chip-genotyped samples. Making use of the Icelandic genealogy, the untyped first-and second-degree relatives of chip-typed individuals were also included in the analysis to increase power 24 . In total, 104,220 chip-typed individuals and 294,212 of their untyped relatives were imputed on the basis of a panel of sequence variants identified through whole-genome sequencing of 2,636 Icelanders to a mean depth of 20×.
GWAS analysis of Icelandic offspring from preeclamptic pregnancies included a total of 1,507 cases (380 chip-typed) and 296,865 controls (91,326 chip-typed). The controls used in this study were Icelandic individuals from other ongoing GWAS studies at deCODE and their relatives. Logistic regression was used to test for association between sequence variants and disease, treating disease status as the response and genotype counts as covariates. Other characteristics also included in the model as nuisance variables were sex, county of birth, current age or age at death (first-and second-order terms included), genotyping status and an indicator function for the overlap of the lifetime of the individual with the timespan of phenotype collection 25 . In order to account for relatedness and stratification within the case and control sample sets, we applied the method of genomic control 25 . Based on a set of about 300,000 common variants distributed across the genome, the inflation in the χ 2 statistic for offspring from preeclamptic pregnancies was estimated to be 1.115.
ALSPAC. A total of 9,912 ALSPAC children were genotyped using the Illumina HumanHap550 quad genome-wide SNP genotyping platform (Illumina) by the Logistics and Genotyping Facilities at the Wellcome Trust Sanger Institute and the Laboratory Corporation of America (LabCorp Holdings). PLINK software (v1.07) was used to carry out quality control measures. Individuals were excluded from further analysis on the basis of having incorrect sex assignment, minimal or excessive heterozygosity (<0.320 and >0.345 for the Sanger data and <0.310 and >0.330 for the LabCorp data), or disproportionate levels of individual missingness (>3%) or for being of nonEuropean ancestry (as detected by a multidimensional scaling analysis seeded with HapMap 2 individuals). EIGENSTRAT analysis revealed no additional obvious population stratification, and genome-wide analyses with other phenotypes in the same cohort indicate a low λ value. SNPs with a MAF <1% and call rate <95% were removed. Furthermore, only SNPs that passed an exact test of Hardy-Weinberg equilibrium (P > 5 × 10 −7 ) were considered for analysis. Related subjects (>10% IBD) who passed all other quality control thresholds were retained during subsequent phasing and imputation; 9,115 subjects and 500,527 SNPs passed these quality control filters.
We combined the 477,482 SNP genotypes in common between the samples from children and mothers. Genotyping and quality control of the ALSPAC mothers can be found elsewhere 26 . SNPs with genotype missingness >1% and those that failed the exact test of Hardy-Weinberg equilibrium were removed. A further 321 participants were removed owing to potential ID mismatches (IBD < 1). The resultant data set comprised 17,842 subjects, of whom 6,305 were mother-offspring pairs. An additional 112 SNPs were removed after liftover of the merged genotyped data from hg18 to hg19 coordinates. Haplotype phasing was performed using SHAPEIT (v2.r644) 23 , and known autosomal variants were imputed with IMPUTE (V2.2.2) 22 using the 1000 Genomes Project reference panel (Phase 1, Version 3) consisting of 2,186 reference haplotypes (including non-Europeans).
Logistic regression, as implemented in SNPTEST (v2.5-beta4) 22 , was used to test for association between imputed genotype probabilities and disease status. Based on a set of ~9 million SNPs (MAF > 0.5% and IMPUTE2 INFO > 0.6), no evidence of genomic inflation was observed (λ GC = 1.008).
Follow-up genotyping. Follow-up variants in the FLT1 locus were chosen to test association with the peak SNP rs4769613 and to test for possible association in the other eight FLT1 LD blocks shown in Supplementary Figure 2 . Some genotyped variants were highly correlated surrogates of rs4769613 or of other follow-up SNPs in case the assay for the primary variant failed and to ensure that assertion of a true positive association did not rely on genotyping of a single variant. Follow-up variants in non-FLT1 regions of the genome were chosen based on their GWAS meta-analysis P value and were selected to further test suggestive evidence of association exhibited by the top GWAS discovery meta-analysis signals. Replication genotyping was performed at the Wellcome Trust Sanger Institute using Sequenom iPLEX assays and at the British Heart Foundation Glasgow Cardiovascular Research Centre using TaqMan Open Array genotyping. Variants were excluded from analysis if they had call rates <95%; subjects with call rates <80% and families in the MoBa cohort that exhibited more than one Mendelian error were also excluded. For four variants (rs7305125, rs149427560, rs12050029 and rs4769628), follow-up data for the MoBa samples were in silico data based on 1,046 cases and 961 controls assayed on the Illumina HumanCoreExome-12 v1.1 chip and imputed based on the 1000 Genomes Project Phase 3 reference panel. Of those, 908 cases and 909 controls were also included in the directly genotyped MoBa replication set.
Meta-analysis.
Prior to meta-analysis, GWAS results were adjusted by a genomic control factor, λ GC , where appropriate, as described above for each GWAS cohort. Study-level variants with MAF <0.5% or an imputation quality score <0.6 were excluded from the analysis. This left 7,476,169 autosomal variants for analysis. The GWAS and the GWAS + replication meta-analyses were conducted using the fixed-effects inverse variance weighting method implemented in MetaSoft 27 . No genomic control adjustment was applied to the GWAS meta-analysis results, as the difference of the inflation factor from 1 was negligible (λ GC = 1.0075).
Conditional and FLT1 region-wide analyses. The association between disease status and a variant conditional on rs4769613 was assessed by inversevariance-weighted meta-analysis of the conditional analyses in each cohort. Individual cohorts were analyzed by logistic regression of the disease status of the cohort against expected genotype dosage, with the expected dosages of conditioning variants included as covariates. This approach was implemented for each cohort as follows: the MoBa and FINNPEC replication cohorts were analyzed using plink --condition; the GOPEC and MoBa GWAS were analyzed using snptest -condition_on; the deCODE association analysis is described above; and ALSPAC conditional associations were inferred from the summary association statistics, using 1000 Genomes Project Phase 3 European samples to estimate the LD structure through the joint analysis method 28 . We assessed the region-wide effective number of tests using the method of Gao 29 on the imputed WTCCC2 UK control data set for the 5,405 common variants (MAF > 5%) within 1 Mb of rs4769613, yielding a total of 832 independent tests and hence a FLT1 region-wide significance threshold of 0.05/832 = 6.01 × 10 −5 .
Analysis of maternal, fetal and parent-of-origin effects. The family genotype data were jointly analyzed using the EMIM method 6 . Subjects were first partitioned into maximal family groups within each cohort (Supplementary Table 9 ). We then fitted EMIM models assuming Hardy-Weinberg equilibrium and exchangeable parental genotypes. We considered two parameter sets: maternal and fetal effects (R 1 , R 2 , S 1 and S 2 ) and maternal, fetal and parent-of-origin effects (R 1 , R 2 , S 1 , S 2 and I m , where I m is the OR associated with maternal transmission of the risk allele). The individual cohort results were combined using inverse-variance-weighted meta-analysis.
Preeclampsia subtype analysis. To analyze the relationship between rs4769613 genotype and preeclampsia subtypes, we pooled genotype and clinical data from the GOPEC, FINNPEC and MoBa cohorts (Supplementary Table 8 ). The phenotype associations were calculated using logistic regression with cohort and FINNPEC recruitment region included as indicator variables. deCODE phenotype database. The deCODE Genetics phenotype database contains medical information on diseases and traits obtained through collaboration with specialists in each field. This includes information on cardiovascular diseases (myocardial infarction, coronary arterial disease, peripheral arterial disease, atrial fibrillation, sick sinus syndrome and stroke), metabolic disorders (obesity, diabetes and metabolic syndrome), psychiatric disorders (schizophrenia, bipolar disorder, anxiety and depression), addictions (nicotine and alcohol), inflammatory diseases (rheumatoid arthritis, lupus and asthma), musculoskeletal disorders (osteoarthritis and osteoporosis), eye diseases (glaucoma), kidney diseases (kidney stones and kidney failure) and 29 types of cancer. Anthropometric measures have also been collected through several of these projects. Routinely measured traits from patient workups (sodium, potassium, bicarbonate, calcium, phosphate, creatinine, blood cell counts, hemoglobin, hematocrit, 15 immunoglobulins, iron, vitamins, lipids, liver function tests and more) were obtained from the Landspitali University Hospital, Reykjavík, and the Icelandic Medical Center Laboratory in Mjodd (Laeknasetrid), Reykjavik. The number of independent and uncorrelated secondary traits tested for association amounted to 400.
Placental expression of Flt1 and sFlt1. Women with singleton pregnancies delivering by caesarean section were recruited to the preeclampsia study between 2002 and 2012 at St. Olavs Hospital, Trondheim University Hospital and Haukeland University Hospital, Bergen. Healthy and preeclamptic pregnancies were included as described previously 30 . A tangential section 100 (100 mg) from the maternal central side of the placenta was collected directly
